Metropolis Acquires Ambika Pathology To Boost Maharashtra Presence

19 Sep 2025 CW Team

Established in 1995 by Dr Rajendra Sadashiv Patil, Ambika Pathology is one of the leading diagnostic providers in the region. It operates a central laboratory supported by 12 patient touchpoints and offers a wide range of tests. Nearly 75 per cent of its revenue comes from walk-in B2C patients, reflecting its strong trust among patients and clinicians in Kolhapur and neighbouring towns.

The acquisition forms part of Metropolis’ “String of Pearls” strategy, which focuses on building regional clusters and improving access to advanced diagnostics across India. The Kolhapur facility will strengthen the company’s Western Maharashtra network, where it already operates 19 laboratories across Pune, Sangli, Satara, Solapur, Nashik, Ahmednagar and Kolhapur, supported by over 200 patient service centres and a growing franchise base.

Ameera Shah, Promoter and Executive Chairperson of Metropolis, said: “Maharashtra contributes nearly 40 per cent of our revenues, making it a key growth market. Ambika Pathology strengthens our regional presence and supports our ambition to make high-quality diagnostics accessible to more communities.”

Surendran Chemmenkotil, Managing Director of Metropolis, added: “Kolhapur is a critical healthcare hub. Ambika Pathology will be developed into a mini regional reference lab, enhancing our specialised diagnostics capabilities and enabling better outcomes through operational excellence and digital innovation.”

Dr Rajendra Patil, Founder of Ambika Pathology, commented: “Joining Metropolis brings global standards of science and technology to our region. This collaboration will widen the scope of specialised tests and create new opportunities for patients and professionals in Western Maharashtra.”

Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), India’s second-largest pathology laboratory chain led by Ameera Shah, has completed its fourth acquisition in the past 10 months with the addition of Dr R.S. Patil’s Ambika Pathology Laboratory in Kolhapur. The NABL-accredited facility has joined the Metropolis network through a Business Transfer Agreement.Established in 1995 by Dr Rajendra Sadashiv Patil, Ambika Pathology is one of the leading diagnostic providers in the region. It operates a central laboratory supported by 12 patient touchpoints and offers a wide range of tests. Nearly 75 per cent of its revenue comes from walk-in B2C patients, reflecting its strong trust among patients and clinicians in Kolhapur and neighbouring towns.The acquisition forms part of Metropolis’ “String of Pearls” strategy, which focuses on building regional clusters and improving access to advanced diagnostics across India. The Kolhapur facility will strengthen the company’s Western Maharashtra network, where it already operates 19 laboratories across Pune, Sangli, Satara, Solapur, Nashik, Ahmednagar and Kolhapur, supported by over 200 patient service centres and a growing franchise base.Ameera Shah, Promoter and Executive Chairperson of Metropolis, said: “Maharashtra contributes nearly 40 per cent of our revenues, making it a key growth market. Ambika Pathology strengthens our regional presence and supports our ambition to make high-quality diagnostics accessible to more communities.”Surendran Chemmenkotil, Managing Director of Metropolis, added: “Kolhapur is a critical healthcare hub. Ambika Pathology will be developed into a mini regional reference lab, enhancing our specialised diagnostics capabilities and enabling better outcomes through operational excellence and digital innovation.”Dr Rajendra Patil, Founder of Ambika Pathology, commented: “Joining Metropolis brings global standards of science and technology to our region. This collaboration will widen the scope of specialised tests and create new opportunities for patients and professionals in Western Maharashtra.”

Infrastructure Urban

18 Nov 2025

PTC Expands Mehsana Plant To Boost Precision Manufacturing

PTC Industries Limited, a leading producer of high-precision castings and advanced materials for critical applications, has commenced a significant expansion of its investment-casting facility in Mehsana, Gujarat. With global supply chains undergoing a strategic realignment, industries are increasingly shifting production to resilient and trusted destinations. India is emerging as a major hub for precision manufacturing, creating substantial opportunities for industrial casting exports. In response, PTC is scaling and modernising its Mehsana site to capture rising global demand. The expansio..

Infrastructure Urban

18 Nov 2025

Apollo Completes Acquisition Of IDL Explosives

Apollo Defence Industries Private Limited, a subsidiary of Apollo Micro Systems Limited, has confirmed the successful completion of its full acquisition of IDL Explosives Limited from GOCL Corporation Limited. With this transaction now concluded, IDL Explosives becomes a step-down subsidiary of Apollo Micro Systems. IDL Explosives operates manufacturing facilities in Rourkela and several other locations across India. Apollo Group plans to expand and strengthen the company’s operations in line with its strategic ambitions within the rapidly growing defence explosives sector. The acquisition..

Infrastructure Urban

18 Nov 2025

GOCL Completes Sale Of IDL Explosives To Apollo Defence

GOCL Corporation Limited has announced the completion of the sale of its subsidiary, IDL Explosives Limited, to Apollo Defence Industries, marking the conclusion of the divestment process approved by shareholders earlier this year. IDL Explosives operates manufacturing units in Rourkela and several other locations nationwide. Apollo Defence plans to expand and reinforce the business in line with its strategic objectives within the rapidly growing defence sector. With this divestment, GOCL and the Hinduja Group complete their strategic exit from the explosives and detonators portfolio. Last y..